Iodine (125I) CC49

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Iodine (125I) CC49?
Monoclonal antibody
Type Whole antibody
Source Mouse
Target TAG-72
Clinical data
Legal status
ATC code V09IX03
Chemical data
Formula ?
 YesY (what is this?)  (verify)

Iodine (125I) CC49 is an iodine-125 radiolabelled monoclonal antibody for the detection of tumours. It is used in radioimmunoassays such as CA 72-4.[1]

CC49 has also been tested for the treatment of solid tumours, but without success. Iodine (131I) CC49 and lutetium (177Lu) CC49, for example, were shown to induce human anti-mouse antibodies; no tumour response was observed in Phase I and II clinical trials.[2]


A wide range of CC49 derivatives has been used in pharmaceutical research. Examples include chimeric[2] and humanized CC49,[3] as well as a fusion protein of a CC49 single-chain variable fragment and the enzyme beta-lactamase.[4]


  1. ^ Guadagni, F.; Roselli, M.; Cosimelli, M.; Spila, A.; Cavaliere, F.; Tedesco, M.; Arcuri, R.; Abbolito, M. R.; Casale, V.; Pericoli, M. N.; Vecchione, A.; Casciani, C. U.; Greiner, J. W.; Schlom, J. (1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay". Cancer Research 56 (22): 5293–5298. PMID 8912871.  edit
  2. ^ a b Trahan Rieger, Paula, ed. (2001). Biotherapy (2nd ed.). Jones and Bartlett. pp. 334–335. ISBN 0-7637-1428-3. 
  3. ^ Milenic, D. E.; Brady, E. D.; Garmestani, K.; Albert, P. S.; Abdulla, A.; Brechbiel, M. W. (2010). "Improved efficacy of α-particle-targeted radiation therapy". Cancer 116 (4 Suppl): 1059–1066. doi:10.1002/cncr.24793. PMID 20127951.  edit
  4. ^ Alderson, R. F.; Toki, B. E.; Roberge, M.; Geng, W.; Basler, J.; Chin, R.; Liu, A.; Ueda, R.; Hodges, D.; Escandon, E.; Chen, T.; Kanavarioti, T.; Babé, L.; Senter, P. D.; Fox, J. A.; Schellenberger, V. (2006). "Characterization of a CC49-Based Single-Chain Fragment−β-Lactamase Fusion Protein for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)". Bioconjugate Chemistry 17 (2): 410–418. doi:10.1021/bc0503521. PMID 16536473.  edit